Renexus® (NT-501), CNTF-secreting cells for treatment of retinal diseases
Renexus® (NT-501) is an allogeneic intra-vitreous implant of the NTC201 human retinal pigment epithelium cell line transfected with a plasmid encoding ciliary neurotrophic factor (CNTF). CNTF has a positive effect on various ocular diseases. Cells are encapsulated inside the NT-501 device.
The implantation procedure was found to be safe with no retinal detachment or increase in intraocular pressure.
Treated retinitis pigmentosa (RP) and macular degeneration patients demonstrated a dose-dependent increase in retinal thickness and inhibition of vision loss.
Read More
Renexus® was granted orphan drug designation by the FDA for retinitis pigmentosa and macular telangiectasia and also a fast-track designation for retinitis pigmentosa and dry age-related macular degeneration.
Read More
Product Information for
Renexus® (NT-501), CNTF-secreting cells for treatment of retinal diseases